Epcoritamab (DuoBody-CD3xCD20)

Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.  

Clinical studies
Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies. For more information on Epcoritamab, visit clinicaltrials.gov.